Ani Pharmaceuticals Inc Receivables Turnover Ratio (ANIP), from the second quarter 2026 to the second quarter 2025 current and historic results, rankings and more - CSIMarket
CSIMarket
 


Ani Pharmaceuticals Inc  (NASDAQ: ANIP)
 

Ani Pharmaceuticals Inc Accounts Receivables Turnover Ratio from the second quarter 2026 to the second quarter 2025

Quarterly Results, Trends, Rankings, Statistics


Ani Pharmaceuticals Inc's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the second quarter 2026 to a ratio of 3.68, above the company average. This is a clear sign of healthy business climate in the Major Pharmaceutical Preparations industry and improving liquidity at their respective customers, during the second quarter 2026. Average receivable collection period, for the Ani Pharmaceuticals Inc in Jun 30 2026 quarter, has decreased to 99 days, compared to 100 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 458 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 1748 to 3075.

What is Receivable Turnover Ratio?
What is Ani Pharmaceuticals Inc Selling?


What is Receivable Turnover Ratio?





ANIP Receivables Turnover Ratio (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Receivable Change 21.63 % 15.93 % 26.77 % 28.65 % 35.86 %
Y / Y Revenue Change 25.87 % 20.46 % 29.64 % 53.58 % 53.12 %
Receivable Turnover Ratio (TTM) 3.68 3.64 3.61 3.59 3.46
ANIP's Total Ranking # 3075 # 1748 # 2697 # 707 # 1371
Accounts Receivable average collection period days 99 100 101 102 105
Seq. Receivable Change 7.45 % -9.13 % 11.27 % 11.95 % 2.41 %
Seq. Revenue Change 12.04 % -3.88 % 8.45 % 7.78 % 7.23 %


Receivable Turnover Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 142
Healthcare Sector # 459
Overall Market # 3075

Receivable Turnover Ratio Statistics
High Average Low
8.58 3.25 1.94
(Jun 30 2013)   (Jun 30 2022)






Financial Statements
Ani Pharmaceuticals Inc's Accounts Receivable $ 274 Millions Visit ANIP's Balance sheet
Ani Pharmaceuticals Inc's Sales TTM $ 978 Millions Visit ANIP's Income Statement
Sources of ANIP's Revenues Visit ANIP's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
ANIP's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
ANIP's Growth Rates ANIP's Roa ANIP's Inventory Turnover Ratio ANIP's Dividend Comparisons
ANIP's Profitability Ratios ANIP's Roi ANIP's Asset Turnover Ratio ANIP's Dividend Growth
ANIP's Valuation Ratios ANIP's Roe ANIP's Financial Strength Ratios ANIP's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Jun 30 2026 Receivable at quarter ending Jun 30 2026
Biolife Solutions Inc   9.67 $ 102.718  Millions$ 10.626  Millions
The Oncology Institute Inc   9.66 $ 587.244  Millions$ 60.780  Millions
Sharps Technology Inc   9.65 $ 1.960  Millions$ 0.203  Millions
Encompass Health Corporation  9.57 $ 6,206.100  Millions$ 648.325  Millions
Septerna Inc   9.42 $ 98.882  Millions$ 10.501  Millions
Biofrontera Inc   9.33 $ 45.956  Millions$ 4.928  Millions
Enanta Pharmaceuticals Inc  9.29 $ 65.258  Millions$ 7.027  Millions
The Pennant Group Inc   9.27 $ 1,101.710  Millions$ 118.798  Millions
Crinetics Pharmaceuticals Inc   9.25 $ 42.156  Millions$ 4.558  Millions
Neuronetics Inc   9.24 $ 154.594  Millions$ 16.732  Millions
Myomo Inc   9.24 $ 44.242  Millions$ 4.790  Millions
Harmony Biosciences Holdings inc   9.22 $ 960.191  Millions$ 104.164  Millions
Bioaffinity Technologies Inc   9.18 $ 5.901  Millions$ 0.643  Millions
Pavmed Inc   9.16 $ 0.126  Millions$ 0.014  Millions
Clene Inc   9.16 $ 0.197  Millions$ 0.022  Millions
Ardent Health Inc   9.16 $ 6,405.940  Millions$ 699.363  Millions
Lexicon Pharmaceuticals Inc   9.14 $ 41.469  Millions$ 4.535  Millions
Novavax inc   9.06 $ 413.796  Millions$ 45.668  Millions
Nuvation Bio Inc   9.05 $ 169.551  Millions$ 18.737  Millions
Cue Biopharma Inc   9.04 $ 37.654  Millions$ 4.165  Millions
Sunshine Biopharma Inc   9.03 $ 35.347  Millions$ 3.916  Millions
Biocryst Pharmaceuticals Inc   9.00 $ 940.613  Millions$ 104.543  Millions
Edwards Lifesciences Corporation  8.99 $ 6,512.500  Millions$ 724.750  Millions
Cannapharmarx Inc   8.86 $ 1.699  Millions$ 0.192  Millions
Grail Inc   8.85 $ 165.263  Millions$ 18.670  Millions
Guardant Health Inc   8.84 $ 1,183.105  Millions$ 133.772  Millions
Zomedica Corp   8.84 $ 35.903  Millions$ 4.063  Millions
Scientific Industries Inc   8.83 $ 5.728  Millions$ 0.649  Millions
Sanara Medtech Inc   8.76 $ 110.116  Millions$ 12.568  Millions
Pacs Group Inc   8.75 $ 5,551.038  Millions$ 634.735  Millions

Date modified: 2026-09-08T15:22:21+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.